公开(公告)号：US20170027957A1

公开(公告)日：2017-02-02

申请号：US15106778

申请日：2014-12-17

Applicant: UNIVERSITY OF MANITOBA

Inventor： Paul FERNYHOUGH ,  Nigel A. CALCUTT

IPC: A61K31/5513 ,  A61K38/17 ,  A61K31/216 ,  A61K9/00

CPC classification number: A61K31/5513 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0053 ,  A61K31/216 ,  A61K31/46 ,  A61K31/496 ,  A61K38/1767 ,  A61K45/06 ,  A61K2300/00

Abstract: A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically acceptable carrier and/or an excipient. The composition is useful for therapy of peripheral neuropathies exemplified by peripheral neuropathies induced by systemic diseases, peripheral neuropathies induced by metabolic diseases, chemotherapy-induced peripheral neuropathies, compression-induced peripheral neuropathies, peripheral neuropathies induced by exposure to dichloroacetate, immune-mediated peripheral neuropathies, peripheral neuropathies induced by infections, and genetically acquired peripheral neuropathies.

Abstract translation: 用于治疗有需要的受试者的周围神经病变的组合物。 该组合物包含有效量的选自哌仑西平，奥昔布宁，毒蕈碱毒素7，毒蕈碱性受体拮抗剂及其组合的药剂，以及药理学上可接受的载体和/或赋形剂。 该组合物可用于治疗由全身性疾病引起的周围神经病变，由代谢疾病引起的周围神经病变，化疗诱发的周围神经病变，压迫性外周神经病变，由暴露于二氯乙酸诱导的周围神经病变，免疫介导的周围神经病 ，感染引起的周围神经病变，以及遗传性获得性周围神经病变。

公开(公告)号：US20210267998A1

公开(公告)日：2021-09-02

申请号：US17206498

申请日：2021-03-19

Applicant: UNIVERSITY OF MANITOBA ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Paul FERNYHOUGH ,  Nigel A. CALCUTT

IPC: A61K31/5513 ,  A61K31/216 ,  A61K9/00 ,  A61K31/496 ,  A61K31/46 ,  A61K45/06 ,  A61K38/17

Abstract: A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically acceptable carrier and/or an excipient. The composition is useful for therapy of peripheral neuropathies exemplified by peripheral neuropathies induced by systemic diseases, peripheral neuropathies induced by metabolic diseases, chemotherapy-induced peripheral neuropathies, compression-induced peripheral neuropathies, peripheral neuropathies induced by exposure to dichloroacetate, immune-mediated peripheral neuropathies, peripheral neuropathies induced by infections, and genetically acquired peripheral neuropathies.